Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049121 | 0.85 | TRPM8 (0.67) | TRPM8BTKMAPT | |
| SCHEMBL27997076 | 0.84 | CDC7 (0.52) | TRPM8SMN1; SMN2KDM4EBTK | |
| SCHEMBL27997095 | 0.82 | GAA (0.43) | SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL28245727 | 0.78 | CYP1A2 (0.48) | TRPM8CYP1A2CYP3A4LMNAALDH1A1 | |
| SCHEMBL28245757 | 0.78 | RAB9A (0.56) | TRPM8SMN1; SMN2KDM4ECYP1A2ALDH1A1 | |
| SCHEMBL15049277 | 0.78 | GAA (0.58) | TRPM8SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL15049019 | 0.76 | TRPM8 (0.77) | TRPM8SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28246576 | 0.75 | MAPT (0.50) | LMNATP53ALDH1A1MAPT | |
| SCHEMBL3436646 | 0.75 | SMN1; SMN2 (0.70) | TRPM8SMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL17374804 | 0.72 | TRPM8 (0.59) | TRPM8SMN1; SMN2KDM4ELMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104220069-B | Trpm8 antagonists | 多姆皮制药公司 | 2018-10-02 | — | — | CN | claimed |
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | claimed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | claimed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | claimed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | claimed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | claimed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | claimed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | claimed |
| CN-104220069-B | Trpm8 antagonists | 多姆皮制药公司 | 2018-10-02 | — | — | CN | disclosed |
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| CN-104220069-A | Trpm8 antagonists | DOMPE SPA | 2014-12-17 | — | — | CN | disclosed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885SMN1; SMN2 899/4885KDM4E 4303/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | TRPM8 1/4885SMN1; SMN2 1028/4885KDM4E 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.